CANCER du SEIN : Adopter un mode de vie sain réduit la récidive et la mortalité

"Ce sont 2 études de la Yale, présentées au 50ème Congrès de l’American Society of Clinical Oncology (ASCO) qui démontrent que des changements de mode de vie sont efficaces contre le cancer du sein. Ici, perte de poids et exercice physique améliorent des biomarqueurs associés à sa récidive et au risque de décès."

http://www.santelog.com/news/cancerologie/can...relasuite.htm#lirelasuite

BREAST CANCER : Adopt a healthy lifestyle to reduce recidivism and mortality

"These are 2 studies at Yale, presented at the 50th Congress of the American Society of Clinical Oncology (ASCO) showing that changes in lifestyle are effective against breast cancer. Here, weight loss and exercise improve biomarkers associated with its recurrence and risk of death."

http://meetinglibrary.asco.org/content/128774-144

http://medicine.yale.edu/cancer/news/article.aspx?id=7483

French Article
http://www.santelog.com/news/cancerologie/can...relasuite.htm#lirelasuite

1- Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

"In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene. The drug also has shown dramatic responses in patients whose lung cancers harbored a different molecular abnormality, namely ROS1 gene rearrangements."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

2- Results in Phase I trial targeting cancer stem cells

"Results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate targeting cancer stem cells (CSCs) have been released. The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open in combinations with standard therapy for pancreatic, ovarian and liver cancers."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

3- One step closer to a breath test for lung cancer

"A test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present, new research shows. The device requires blowing up a balloon, which is then attached to an extremely sensitive gold nanoparticle sensor. The particles in the sensor trap and then help to analyze volatile organic compounds in the exhaled breath."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

4- Patients with metastatic colon cancer respond to new combination therapy

"In an aggressive disease known for poor response rates, researchers found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. "What's promising is the fact that we're seeing these high response rates in early studies which suggests this could become a new standard of care down the line," one researcher said. "There's clearly some kind of synergistic activity with the combination."."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

5- Immune therapy for advanced bladder cancer yields promising results

"A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 is a protein expressed by many tumor types that can render the cancer invulnerable to immune attack."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

6- Ibrutinib as second-line therapy for chronic lymphocytic leukemia supported by study

"In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia, ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study. Ibrutinib is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

7- Prevalence of new genetic driver in lung cancer shown in study

"A line has been drawn from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. "Everything we know about lung cancer points to the idea that when we find one of these genetic drivers and can target it with a drug, patients will respond and tend to have a good amount of time on drug before it becomes ineffective. Obviously we can't guarantee the effectiveness of targeting the NTRK1 mutation at this point, but everything we know about these kinds of genes makes us extremely hopeful," says one researcher."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

8- Preventing early menopause in breast cancer patients with new drug treatment

"Among young breast cancer patients, one of the most distressing side effects of chemotherapy is early menopause. But a major study finds the risk of early menopause can be significantly reduced by adding the drug goserelin to the chemotherapy regimen."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

1- 'Quadrapeutics' works in preclinical study of hard-to-treat tumors: Animal tests show technology effective against aggressive cancer

"The first preclinical tests for a novel anti-cancer technology called 'quadrapeutics' that converts current clinical treatments to instantaneously detect and kill only cancer cells have been successful. Quadrapeutics combines clinically available drugs, colloidal gold, pulsed lasers and radiation in a novel and safe micro-treatment that improved standard therapy by 17-fold against aggressive, drug-resistant tumors."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

2- Smokers with gene defect have one in four chance of developing lung cancer

"Around a quarter of smokers who carry a defect in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals. Scientists announce a previously unknown link between lung cancer and a particular BRCA2 defect, occurring in around 2 per cent of the population."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

3- Drug combination extends survival by more than a year in metastatic prostate cancer

"Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists. The dramatic results in a multi-center phase III trial should change the way physicians have routinely treated such patients since the 1950s, they said."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

4- Newly identified brain cancer mutation will aid drug development

"New genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma has been identified by an international team of researchers. The researchers identified a genetic mutation in the tumor cells that plays a role in both the growth and the death of a cell. Additionally, the mutation to the newly identified gene may also contribute to the tumor’s resistance to radiation."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

5- Increasing sensitivity of HPV detection in cancer with new test

"Results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral and cancer mutations have been released by researchers. The panel identified human papilloma virus (HPV) sequences undetected by conventional laboratory tests as well as new unreported HPV mutations. It is estimated that each year there are approximately 30,000 cases of HPV-associated cancers in the US."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

6- Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without compromising care

"Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study."

http://www.sciencedaily.com/releases/2014/05/...ily%3A+Top+Health+News%29

More to the previous post, here are the conclusions:
The Plenary studies are:

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer: Post-surgery (adjuvant) exemestane is more effective at preventing breast cancer recurrences than tamoxifen when given with ovarian function suppression in young women with hormone receptor-positive, early breast cancer, reducing the relative risk of developing a recurrent cancer by 28 percent.

Addition of docetaxel to initial hormone therapy substantially improves survival in men with metastatic, hormone-sensitive prostate cancer: The findings suggest inclusion of docetaxel in first-line therapies for men with advanced disease who are healthy enough for chemotherapy, especially those with extensive disease spread.

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer: Large U.S.-funded head-to-head comparison trial answers a long-standing question about the relative effectiveness of four common regimens, offering patients and providers new reassurance as they face treatment decisions.

Adding lapatinib to adjuvant trastuzumab does not improve outcomes for women with early-stage HER2-positive breast cancer: Results from the phase III ALTTO study indicate that post-surgery treatment with the two anti-HER2 drugs does not improve disease-free survival compared to standard treatment with trastuzumab alone.

1- Gene therapy combined with IMRT reduces rate of positive prostate biopsy after treatment for intermediate-risk prostate cancer patients

"Combining oncolytic adenovirus-mediated cytotoxic gene therapy (OAMCGT) with intensity modulated radiation therapy (IMRT) reduces the risk of having a positive prostate biopsy two years after treatment in intermediate-risk prostate cancer without affecting patients’ quality of life, research has determined."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

2- One in four children with leukemia not taking maintenance medication, study shows

"An estimated 25 percent of children in remission from acute lymphocytic leukemia are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study. Acute lymphocytic leukemia (ALL), a cancer of the white blood cells, is the most common form of childhood cancer. While more than 95 percent of children with ALL enter remission within a month of receiving initial cancer therapy, one in five will relapse. In order to remain cancer-free, children in remission must take a form of oral chemotherapy every day for two years."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

3- Worry, behavior among teens at higher risk for breast cancer : Focus of new study

"Teenage girls with a familial or genetic risk for breast cancer worry more about getting the disease, even when their mother has no history, compared to girls their age with no known high risks, according to new data. Early analyses suggest that such worry may increase risk behavior, such as smoking and potentially alcohol use, but does not appear to influence positive behavior, such as exercise."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

4- Long-term results encouraging for combination immunotherapy for advanced melanoma

"The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results -- long-lasting with high survival rates -- researchers report. The trial evaluated the safety and activity of the combination regimen of nivolumab (anti-PD-1), an investigational PD-1 immune checkpoint inhibitor, and ipilimumab (anti-CTLA-4; Yervoy), given either concurrently or sequentially, to patients with advanced melanoma whose disease progressed after prior treatment."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

5- Harnessing power of immune system for therapies against cancer

"Innovative immunotherapies treatments for advanced or high-risk melanoma and cervical cancer -- used alone or in combination -- fight cancer by activating and amplifying the body's immune response to the disease. New studies find high activity with investigative drugs for advanced melanoma, and show for the first time that ipilimumab, a treatment already approved for advanced melanoma, can substantially decrease the risk of melanoma recurrence in certain patients with earlier-stage disease."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

6- Common, hard-to-treat cancers: Potential new targeted therapies

"Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted recently by researchers. Findings from the mid- and late-stage trials suggest new ways to slow disease progression and improve survival for patients who experience relapses or resistance to available treatments."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

7- Why colon cancer metastasis always follows the same invasive pattern

"The genes that favor staggered colon cancer metastasis have been discovered by researchers. Of the colon cancer patients that develop metastases, 40% present metastasis first to the liver and later to the lung, always in this clinical order of appearance. The study reveals that the metastatic lesion in the liver is necessary for later metastasis to lung to occur, the former thus becoming a platform from which the cells prepare the subsequent lung metastatic niche to be colonized."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

8- Ovarian cancer subtypes may predict response to bevacizumab

"Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a study has found. The U.S. spends about $3 billion a year on bevacizumab for cancer treatment. "Unfortunately, two-thirds of those patients don't respond to the drug, which means we are just giving them toxicity with no benefit. This expression data will help us choose which patients should receive this drug," a researcher notes."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

9- Early palliative support services help those caring for patients with advanced cancer

"Those caring for patients with advanced cancer experienced reduced depression and felt less burdened by caregiving tasks when palliative support services were offered soon after the patient’s diagnosis. "Family caregivers are a crucial part of the patient care team. Because the well-being of one affects the well-being of the other, both parties benefit when caregivers receive palliative care," said the senior study author."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

10- Moving toward quality patient-centered care at cancer hospital

"Patient navigation and survivorship programs were the focus of a new survey, and the challenges many of these programs face. Results indicate that nearly half of respondents had both a navigation and survivorship program at their institution. Full-time navigators had an average patient load of 100-400 patients, in various phases of the cancer continuum of screening, diagnosis, treatment, and posttreatment."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

11- Weight loss surgery also safeguards obese people against cancer

"Weight loss surgery might have more value than simply helping morbidly obese people to shed unhealthy extra pounds. It reduces their risk of cancer to rates almost similar to those of people of normal weight. This is the conclusion of the first comprehensive review article taking into account relevant studies about obesity, cancer rates and a weight loss procedure called bariatric surgery."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

12- New device isolates most aggressive cancer cells

"Not all cancer cells are created equal: some stay put in the primary tumor, while others move and invade elsewhere. A major goal for cancer research is predicting which cells will metastasize, and why. A cancer research team is taking a new approach to screening for these dangerous cells, using a microfluidic device they invented that isolates only the most aggressive, metastatic cells."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

13- Many breast cancer patients don't get treatment for heart problems

"About 12 percent of older breast cancer patients developed heart failure within three years, often as a result of the cancer drugs and treatments. Despite this, only a third of older breast cancer patients saw a cardiologist within 90 days of developing heart problems. Those who saw a cardiologist were more likely to receive standard drugs for heart failure than those who didn't, researchers report."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

14- New test predicts if breast cancer will spread

"A test that counts the number of locations in tumor specimens where tumor cells may invade blood vessels predicted the risk of distant spread, or metastasis, for the most common type of breast cancer. To measure the test's effectiveness, the researchers used it on about 500 breast tumor specimens that had been collected over a 20-year period. The test proved more accurate in predicting the risk of distant tumor spread than a test closely resembling the leading breast cancer prognostic indicator on the market."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

15- Process to help personalize treatment for lung cancer patients developed

"A process to analyze mutated genes in lung adenocarcinoma to help better select personalized treatment options for patients has been developed by researchers. Adenocarcinoma is the most common type of lung cancer in the United States with approximately 130,000 people diagnosed each year. The study investigated 10 highly mutated and altered genes that contribute to cancer progression, termed oncogenic driver genes, in more than 1,000 lung cancer patients."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

16- Stopping the spread of breast cancer: Newly discovered pathway may advance treatment

"A new pathway that can stop breast cancer cells from spreading has been discovered by researchers. Working with human cancer cells and a mouse model of breast cancer, scientists identified a new protein that plays a key role in reprogramming cancer cells to migrate and invade other organs. When that protein is removed from cancer cells in mice, the ability of the cells to metastasize to the lung is dramatically decreased."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

17- Liver cancer vaccine effective in mice

"Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice. Liver cancer is among the fastest-growing and deadliest cancers in the United States with a 17 percent three-year survival rate. Vaccines help direct the immune system to attack invaders by showing it a representative substance, called an antigen, that the body will recognize as foreign, in this case, AFP for liver cancer."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29

18- Screening has prevented half a million colorectal cancers

"An estimated half a million cancers were prevented by colorectal cancer screening in the United States from 1976 to 2009, report researchers. During this more than 30-year time span, as increasing numbers of men and women underwent cancer screening tests -- including fecal occult blood testing, sigmoidoscopies, and colonoscopies -- colorectal cancer rates declined significantly, the researchers found."

http://www.sciencedaily.com/releases/2014/06/...ily%3A+Top+Health+News%29